SRR12202459
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.390
- G2M_CHECKPOINT+0.280
- E2F_TARGETS+0.250
- MYC_TARGETS_V1+0.250
- UV_RESPONSE_DN+0.240
- PROTEIN_SECRETION+0.230
- ANDROGEN_RESPONSE+0.220
- APOPTOSIS+0.140
- OXIDATIVE_PHOSPHORYLATION+0.100
- UNFOLDED_PROTEIN_RESPONSE+0.050
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.360
- IL6_JAK_STAT3_SIGNALING-0.300
- KRAS_SIGNALING_DN-0.270
- ALLOGRAFT_REJECTION-0.230
- ANGIOGENESIS-0.210
- APICAL_JUNCTION-0.210
- APICAL_SURFACE-0.200
- INFLAMMATORY_RESPONSE-0.200
- GLYCOLYSIS-0.190
- UV_RESPONSE_UP-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R157 | — | — | 0.807 |
| 2 | SJEPD030795_D2.RNA-Seq | EPN | Posterior Fossa EPN | 0.805 |
| 3 | MDT-AP-0155 | Med | Medulloblastoma | 0.792 |
| 4 | R361 | — | — | 0.786 |
| 5 | SJEPD030580_D1.RNA-Seq | EPN | EPN Tumor | 0.771 |
| 6 | SRR26320097 | — | — | 0.766 |
| 7 | MNG730 | — | — | 0.763 |
| 8 | TCGA-BH-A204-01A-11R-A157-07 | — | B | 0.761 |
| 9 | MBCProject_2346_T1_RNA | — | B | 0.760 |
| 10 | MDT-AP-3311 | Med | Medulloblastoma | 0.759 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.390 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.280 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.040 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.030 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.020 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.010 | Inavolisib | — uncovered |